Etzer Darout
Stock Analyst at Barclays
(4.51)
# 261
Out of 5,179 analysts
171
Total ratings
48.57%
Success rate
30.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $142 → $148 | $103.20 | +43.41% | 2 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $113 → $119 | $101.53 | +17.21% | 7 | Mar 19, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $16 | $4.42 | +261.99% | 15 | Mar 19, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Overweight | $48 → $50 | $44.70 | +11.86% | 2 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Outperform | $143 → $128 | $85.45 | +49.80% | 5 | Mar 11, 2026 | |
| MGNX MacroGenics | Maintains: Overweight | $3 → $4 | $2.85 | +40.35% | 11 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $50 → $70 | $43.26 | +61.81% | 10 | Mar 4, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $78 → $79 | $57.30 | +37.87% | 5 | Mar 4, 2026 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $7 | $2.43 | +188.07% | 7 | Feb 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Overweight | $224 | $183.04 | +22.38% | 1 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $11.40 | +136.84% | 9 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $8.40 | +257.14% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $3.39 | +224.48% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $117 | $91.29 | +28.16% | 3 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $41 → $44 | $41.80 | +5.26% | 6 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $119 → $133 | $79.72 | +66.83% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $13.76 | +103.49% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.23 | +119.20% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $30.28 | -20.74% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.22 | +76.13% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $16.99 | +5.94% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $52.88 | +5.91% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $23.01 | +52.11% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $7.60 | +268.66% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.11 | +1,861.41% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $51.74 | +141.59% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $5.57 | +133.39% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $6.84 | -56.14% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $14.74 | +137.45% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.07 | +5,815.49% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.33 | +1,937.74% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $97.98 | +36.76% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $25.96 | +84.90% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $149.85 | -19.92% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.15 | +421.74% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $193.75 | -57.68% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.53 | +319.43% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $320.41 | -46.94% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $88.13 | -56.88% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.55 | +1,364.79% | 1 | Mar 28, 2018 |
ABIVAX Société Anonyme
Mar 24, 2026
Maintains: Overweight
Price Target: $142 → $148
Current: $103.20
Upside: +43.41%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $113 → $119
Current: $101.53
Upside: +17.21%
CytomX Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $10 → $16
Current: $4.42
Upside: +261.99%
Oruka Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $48 → $50
Current: $44.70
Upside: +11.86%
BioNTech SE
Mar 11, 2026
Maintains: Outperform
Price Target: $143 → $128
Current: $85.45
Upside: +49.80%
MacroGenics
Mar 10, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.85
Upside: +40.35%
Scholar Rock Holding
Mar 4, 2026
Maintains: Outperform
Price Target: $50 → $70
Current: $43.26
Upside: +61.81%
AnaptysBio
Mar 4, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $57.30
Upside: +37.87%
C4 Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.43
Upside: +188.07%
Jazz Pharmaceuticals
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $183.04
Upside: +22.38%
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $11.40
Upside: +136.84%
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $8.40
Upside: +257.14%
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.39
Upside: +224.48%
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $91.29
Upside: +28.16%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $41.80
Upside: +5.26%
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $79.72
Upside: +66.83%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $13.76
Upside: +103.49%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.23
Upside: +119.20%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $30.28
Upside: -20.74%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.22
Upside: +76.13%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $16.99
Upside: +5.94%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $52.88
Upside: +5.91%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $23.01
Upside: +52.11%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $7.60
Upside: +268.66%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.11
Upside: +1,861.41%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $51.74
Upside: +141.59%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.57
Upside: +133.39%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $6.84
Upside: -56.14%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $14.74
Upside: +137.45%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.07
Upside: +5,815.49%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.33
Upside: +1,937.74%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $97.98
Upside: +36.76%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $25.96
Upside: +84.90%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $149.85
Upside: -19.92%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.15
Upside: +421.74%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $193.75
Upside: -57.68%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.53
Upside: +319.43%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $320.41
Upside: -46.94%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $88.13
Upside: -56.88%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.55
Upside: +1,364.79%